Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients

Trial Identifier: D3250R00113
Sponsor: AstraZeneca
NCTID:: NCT05603845
Start Date: February 2023
Primary Completion Date: March 2025
Study Completion Date: March 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Colombia Cali, Colombia, 760042
Colombia, Antioquia Medellin, Antioquia, Colombia, 50621
Colombia, Atlantico Soledad, Atlantico, Colombia, 83001
Colombia, Capital District Bogota, Capital District, Colombia, 110111
Colombia, Cundinamarca Bogota, Cundinamarca, Colombia, 111511
Colombia, Risaralda Pereira, Risaralda, Colombia, 660001
Colombia, Santander Floridablanca, Santander, Colombia, 681004
Colombia, Tolima Ibague, Tolima, Colombia, 730006
Dominican Republic, Santiago de los Caballeros Santiago de los Caballeros, Dominican Republic, 51000
Dominican Republic, Santo Domingo Ensanche la Fe, Santo Domingo, Dominican Republic, 10514
India, Gujarat Vadodara, Gujarat, India, 390007
India, Tamil Nadu Chennai, Tamil Nadu, India, 600078
India, Telanagana Hyderabad, Telanagana, India, 500084
Kuwait, Shamiya-Kuwait Shamiya, Shamiya-Kuwait, Kuwait, 8VGW+6RW
Qatar Doha, Qatar
Saudi Arabia Jeddah, Saudi Arabia, 23214
Saudi Arabia Jeddah, Saudi Arabia, 23431
Saudi Arabia, Central Riyadh, Central, Saudi Arabia, 11525
Saudi Arabia, Central Riyadh, Central, Saudi Arabia, 11211
United Arab Emirates Abu Dhabi, United Arab Emirates
United Arab Emirates Jeddah, United Arab Emirates, 23214
United Arab Emirates Riyadh, United Arab Emirates
United Arab Emirates, Abu Dhabi-UAE Abu Dhabi, Abu Dhabi-UAE, United Arab Emirates